Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.
about
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteinsGemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavirLipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis.Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor α-mediated superoxide dismutase induction in HeLa cells.Gemfibrozil ingestions reported to Texas poison control centers, 2000-2005.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats.Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.Inhibition of rat liver microsomal fatty acid chain elongation by gemfibrozil in vitro.Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR- rats.The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically generated gemfibrozil 1-O-acyl glucuronide in the isolated perfused rat liver.Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation.Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
P2860
Q28328142-7B9ED6A8-FB78-4CA7-9183-9BCADC5C50E7Q33625135-8DE63AC6-8755-4324-AFCC-434C1632B453Q35802180-295B412A-83D9-4ACB-9730-3E8149150D67Q35826894-196EB452-055A-4BFA-96BB-E2B5B84855C8Q36053274-51A58D7B-4B2F-4964-AB9E-F31A0E24947CQ36059868-642D7487-EBBD-4288-AEB6-824D3250FB5CQ36195955-4D63BB6F-8F8B-4B5F-A8AC-B5FD6576B797Q37020264-AD71DA35-3DA6-4C18-A55E-1AC9A01EAAEDQ38933872-43D3D453-BD8B-4106-A720-7A5928FC8FADQ40346102-2B4E6B3C-2D7B-4D89-8A01-9E4D92FE5009Q41947131-C2610533-6388-4F48-893F-76FFBF4E9B1DQ42074404-8B1A68B4-571F-4278-ABB2-9DE62C5B40D1Q43959895-3791DFDE-D4C3-4BF0-92AF-6C9B013F357AQ44614900-EB412810-161B-4EB7-9B17-A78EC5CCC13DQ44648377-3B5EC729-2032-48F4-9CDE-D6784C09175EQ47133234-F5BBE42C-292E-4A03-BE95-BA0A47AF3A9FQ57684574-0F747ABE-F714-40F5-B3E0-408AB6A445AA
P2860
Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@en
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@nl
type
label
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@en
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@nl
prefLabel
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@en
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@nl
P1433
P1476
Gemfibrozil. A review of its p ...... rapeutic use in dyslipidaemia.
@en
P304
P356
10.2165/00003495-198836030-00004
P577
1988-09-01T00:00:00Z
P6179
1051255394